ABSTRACT-The mechanisms for the antidiuretic effects of dynorphin (DYN), an endogenous K-agonist, microinjected into the hypothalamic supraoptic (SON) and paraventricular (PVN) nuclei were investigated. DYN decreased the urine outflow rate dose-dependently from 5 to 20 nmol in the SON and PVN, and it in creased vasopressin release. Microinjection of des-Tyr-DYN (a non-opioid peptide) into the SON produced antidiuretic effects with similar potency to that of the DYN-induced effects. However, in the PVN, the effects of des-Tyr-DYN were very markedly weaker than those of DYN. The DYN-induced antidiureses in the SON were partially inhibited by phenoxybenzamine, timolol and atropine, but not by naloxone. Those in the PVN were partially inhibited by naloxone, timolol and atropine, but not by phenoxybenzamine. Syn thetic specific K-agonists, U50,488H and Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Arg-Leu-Arg-Gly 5 aminopentylamide (DAKLI), microinjected into the PVN also produced antidiuretic effects in a dose-de pendent manner. The order of antidiuretic potency was DAKLI > DYN > U50,488H, which was the same as that of K-receptor binding affinity. The DAKLI-induced antidiureses in the PVN were not inhibited by nalox one. These results suggested that DYN caused antidiureses by vasopressin release, through adrenergic and cholinergic mechanisms in the SON and PVN. Only the DYN-induced effects in the PVN were mediated, at least partially, through opioid receptors, perhaps the x-subtype. Immunohistochemical studies show the presence of fibers and terminals of opioid neurons (1-3) in the hypothalamic supraoptic (SON) and paraventricular (PVN) nuclei. Also, cell bodies of vasopressin-containing neurons are localized in these nuclei. Numerous reports suggest that opioid neurons in the hypothalamus, the SON or PVN regulate the urine outflow rate. Intra cerebroventricular injection and microinjection into the nuclei of p and o-opioid agonists decrease the urine outflow rate (4 8). These antidiuretic effects, at least in part, appear to be induced by increased vasopressin re lease, although there are some reports that the opioid agonists show decrease or have no effect on the firing rate of vasopressin-containing neurons or vasopressin release (4, 9-13). On the other hand, c-agonists injected into the ventricle decrease vasopressin release and induce diuretic effects (14-16). Systemic administered K-agonists also elic it the same effects, which are suggested to be mediated through K-receptors on the neurohypophysis (16-19).
Immunohistochemical studies show the presence of fibers and terminals of opioid neurons (1) (2) (3) in the hypothalamic supraoptic (SON) and paraventricular (PVN) nuclei. Also, cell bodies of vasopressin-containing neurons are localized in these nuclei. Numerous reports suggest that opioid neurons in the hypothalamus, the SON or PVN regulate the urine outflow rate. Intra cerebroventricular injection and microinjection into the nuclei of p and o-opioid agonists decrease the urine outflow rate (4 8) . These antidiuretic effects, at least in part, appear to be induced by increased vasopressin re lease, although there are some reports that the opioid agonists show decrease or have no effect on the firing rate of vasopressin-containing neurons or vasopressin release (4, (9) (10) (11) (12) (13) . On the other hand, c-agonists injected into the ventricle decrease vasopressin release and induce diuretic effects (14) (15) (16) . Systemic administered K-agonists also elic it the same effects, which are suggested to be mediated through K-receptors on the neurohypophysis (16) (17) (18) (19) .
In our preliminary study, however, microinjection of dynorphin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (DYN), an endogenous K-agonist (20, 21) which co-exists with vasopressin (22) , into the SON and PVN decreased the urine outflow rate (23) . Thus, we investigated the mechanisms of the DYN-induced anti diuretic effects in this study.
MATERIALS AND METHODS
Male Wistar rats (280-330 g), starved overnight but allowed free access to water, were used. They were orally loaded with tap water (5 ml/100 g body weight); and 45 min later, they were anesthetized by oral administration of the same volume of 12% ethanol. The trachea, the uri nary bladder and the jugular vein were cannulated with polyethylene tubes. The rats were placed in a stereotaxic instrument (Takahashi Co., Tokyo). A stainless steel can nula (outer diameter: 200 pm) was implanted into the SON (coordinates: 6.3 mm anterior to the lamda, 1.3 mm lateral to the midline, 9.0 mm from the dura) or PVN (coordinates: 5.6 mm, 0.3 mm, 8.0 mm), according to at las of Konig and Klippel (24) . Urine drops flowing from the urinary bladder cannula were counted every 10 min by a photoelectric counter (Unique Medical Inc., Tokyo). Effects of drugs on the urine outflow rate were expressed as a percentage of the control level (value for 10 min be fore administration of a drug). Locke's solution contain ing 3% ethanol was continuously infused at a rate of 0.1 ml/min through the jugular vein cannula. The urine out flow rate was constant (approx. 0.1 ml/min) for approx. 5 hr from 30-60 min after the system was set-up. A drug solution (1 p1, dissolved in saline) followed by artificial cerebrospinal fluid (2 pl) to wash out the drug were microinjected into the nucleus through a microsyringe connected to the stainless steel cannula in the nucleus. The microinjection of a drug was carried out for 10 min. Saline was used as the vehicle. The influence of an an tagonist on agonist-induced effects was estimated by com paring the effects of the agonist before and after microin jection of the antagonist in one rat. The interval time be tween the injection of the antagonist and the agonist was 50 90 and 80 -120 min for 300 and 600 nmol naloxone (NAL), respectively, 50 90 min for atropine (ATR), 20 60 min for phenoxybenzamine (PHE) and 30 50 min for timolol (TIM).
Urine was collected during 10-30 min for measure ment of urinary osmotic pressure when DYN showed its maximum effects. The freezing point depression method (The Fiske Osmometer, Model G-62; Fiske Associate, Inc., Uxbridge, MA, USA) was used for the measure ment.
Plasma vasopressin level was measured by radioim munoassay (25) . A blood sample was collected from the trunk after decapitation at 20-25 min after injection of DYN. The plasma, separated by centrifugation, was pumped through sep-pak® (Water Associates, Milford, MA, USA) for concentration. The eluate was dried under nitrogen gas and then dissolved in 0.25 ml of the buffer solution (0.05 M Na2HPO4, 0.01 M KH2PO4, 1.1 MM EDTA, 0.1 mM NaOH and 0.15010 bovine serum albu min, pH 7.4) for radioimmunoassay. The recovery of vasopressin was 79 ± 9.8 % (n = 8).
In some rats, four indices: mean blood pressure, heart rate, respiratory rate and rectal temperature were moni tored simultaneously with the urine outflow rate. A poly ethylene cannula, attached to a pressure transducer (MPU-0.5-290-III; Nihon Kohden Kogyo, Co., Tokyo), was inserted into the carotid artery for direct measure ment of blood pressure. Heart rate was measured with an electrocardiograph (FD-14; Fukuda, Tokyo). Respiratory rate and rectal temperature were measured by thermister probes inserted into the tracheal cannula and the rectum, respectively (SR-115S and MGA 111-219, Nihon Kohden Kogyo, Co.).
Injection sites of the drug into the nuclei were verified by microinjection of methylene blue or by burning with an electric current (3 mA, 60 sec, Lesion Generator Model RFG-4A; Radionics, Inc., Burlington, MA, USA) after the experiments. After 15-pm coronal sections were cut with a microtome (Tissue-Tek II; Miles, Inc., Erkhart, IN, USA) and then stained with Hematoxylin Eosin, the sites of the tip of the cannula were confirmed under the microscope.
The data were presented as the mean±S.E. Statistical analysis for the two means was performed by Student's t test. To judge the total inhibition by the antagonists, two way ANOVA was used. Differences were considered sig nificant when the P value was less than 0.05.
The following drugs were used: dynorphin(1-13), Tyr Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Arg-Leu-Arg-Gly (2 13) (des-Tyr-dynorphin), EDTA, bovine serum albumin and Arg8-vasopressin (grade VI) (Sigma Chemical Co., St. Louis, MO, USA); atropine sulfate (Iwaki Co., Tokyo);
antibody (Calbiochem-Behring, A Division of American Hoechst Co., La Jolla, CA, USA). Naloxone hydrochloride (Sankyo Co., Tokyo) and timolol malate (Nippon Merck-Banyu Co., Tokyo) were generous gifts. The other chemicals were of the highest analytical grade available.
RESULTS

Effects of DYN on urine outflow rate
Vehicle alone, microinjected into the SON or PVN, had no effect on the urine outflow rate (Fig. 1) . The control urine outflow rate was constant at approx. 0.1 ml/min.
As shown in Fig. la , microinjection of DYN(5-20 nmol) into the SON decreased the urine outflow rate in time and dose-dependent manners, and DYN(5-20 nmol) microinjected into the PVN also elicited antidiuret ic effects with almost the same potency (Fig. lb) . When DYN was microinjected into the nucleus of the same rat twice, the antidiureses induced by the first and second in jections were not significantly different at each time point (SON: n=5, PVN: n=3; data not shown).
Effects of D YN on urinary osmotic pressure
Urinary osmotic pressure was simultaneously measured with the urine outflow rate after microinjection of 20 nmol DYN into the nuclei and after intravenous injection of 4 mU vasopressin. The vehicle had no effect on the osmotic pressure and the outflow rate of urine. DYN increased urinary osmotic pressure up to 248±43010 and 480± 103% of the control level in the SON and PVN, respectively (SON: n=5, PVN: n=5; P<0.05) when the antidiuretic effects were maximum: 15±4010 of the control level (0.094±0.016 ml/min) in the SON and 17 ± 5 010 of the control level (0.085 ± 0.008 ml/min) in the PVN. The control osmotic pressure was 279±19 mOsm/kg in the SON and 270±23 mOsm/kg in the PVN. These effects returned to the control level at ap prox. 90 min after the injection.
Intravenous injection of 4 mU vasopressin induced anti diuretic effects with a time-course similar to that of the DYN-induced ones. At 20 min after administration of vasopressin, the urine outflow rate and urinary osmotic pressure were 10±2010 and 338±56010 of the control level (0.067±0.016 ml/min and 315±41 mOsm/kg) (n=4), respectively. They were approximately equal to those of 20 nmol DYN microinjected into the nuclei.
Effects of D YN on plasma vasopressin level
Effects of DYN (20 nmol), microinjected into the SON and PVN, on the plasma vasopressin level were studied. The control vasopressin level was lower than the sensitiv ity of the radioimmunoassay, < 2.4 pg/ml. The vasopres sin level at 30 min after the microinjection of the vehicle into the nuclei was also less than the sensitivity (SON: n=3, PVN: n=5).
Microinjection of DYN into the SON significantly elevated the plasma vasopressin level in six out of eight experiments, with a mean value of 15 ± 5.3 pg/ml. In the other two experiments, the plasma vasopressin level was less than the sensitivity of the assay. In the PVN, six ex periments showed an increase up to 23 ± 7.1 pg/ml from the control level, < 2.4 pg/ml by DYN, and only one ex periment showed an undetectable level.
Effects of D YN on visceral functions
Mean blood pressure, heart rate, respiratory rate and rectal temperature were monitored during the antidiuretic effects induced by DYN (20 nmol). None of the indices changed significantly (SON: n=3, PVN: n=3; data not shown).
Effects of naloxone on the DYN-induced antidiuretic effects
Effects of naloxone (NAL) at 300 or 600 nmol on the antidiuretic effect of 10 nmol DYN were studied. The microinjection of 300 nmol NAL alone into both the nuclei, which was enough to inhibit the morphine-in duced antidiuretic effects in the same method (7), did not show any significant effects on the urine outflow rate. However, 600 nmol of NAL produced antidiuretic effects in the nuclei.
NAL at 300 nmol did not influence the DYN-induced antidiureses in the SON and PVN. NAL at 600 nmol tend ed to attenuate the effect in the SON, but not significantly (Fig. 2a) . In the PVN, the high dose of NAL significantly inhibited the effect at 40-60 min after the microinjection, but the antidiureses still remained (Fig. 2b) . Also, the total inhibition was valid by ANOVA.
Effects of des-Tyr-DYN on urine outflow rate
Effects of des-Tyr-DYN, a non-opioid peptide, on the urine outflow rate were examined to determine if opioid receptors intervene in the DYN-induced effects.
Des-Tyr-DYN at 20 nmol, microinjected into the SON, showed similar antidiuretic effects to those of the same dose of DYN (Fig. 3a) . However, in the PVN, it produced significantly weaker antidiureses as compared with the DYN-induced ones (Fig. 3b) . Effects of adrenergic and cholinergic antagonists on the DYN-induced antidiuretic effects Phenoxybenzamine (PHE, 80 nmol), timolol (TIM, 100 nmol) and atropine (ATR, 300 nmol) were used to investigate whether the DYN-induced effects involve adrenergic and cholinergic mechanisms (Fig. 4) . These doses of the antagonists were enough to block anti diureses induced by norepinephrine, isoproterenol or ACh, respectively (26) (27) (28) .
PHE did not have any effects on the DYN (10 nmol) induced effects in the PVN. PHE and ATR in the SON and TIM in both the nuclei partially inhibited the effects. In the PVN, ATR significantly inhibited the effects of DYN only at 30 min after the injection, although the total inhi bition was not effective according to ANOVA. PHE or ATR alone did not change the urine outflow rate sig nificantly. TIM increased the urine outflow rate to 177-L31016 of the control level (0.092-L0.013 ml/min) in the SON (n=6) and 158--t29% of the control level (0.087±0.010 ml/min) in the PVN (n=6). 
Effects of U50,488H and DAKLI on urine outflow rate
Synthetic specific K-agonists, U50,488H and DAKLI, microinjected into the PVN decreased the urine outflow rate in a dose-dependent manner (Fig. 5) . DAKLI produced the most potent effects among the three x agonists. The DAKLI (5 nmol)-induced antidiureses were not inhibited by pre-microinjection of NAL at 600 nmol into the PVN. The following percentages were for the urine outflow rate induced by DAKLI with the pretreat ment vs. without the pretreatment: 102±7% vs. 97±6% at 10 min, 24±8% vs. 26±10% at 20 min, 22±6% vs. 92± 19% of the control level (0.086±0.012 ml/min) at 60 min after the injection (n=5). 
DISCUSSION
The SON and PVN include cell bodies of vasopressin containing neurons, terminals of DYN-containing neurons (2, 3) and K-opioid receptors (7, 29) . In this study, we observed that microinjection of the three K-agonists, DYN, U50,488H and DAKLI, into the PVN produced antidiuretic effects with the potency order of DAKLI > DYN > U50,488H. This order is consistent with the one for K-receptor binding affinity (30) . In the PVN, the DYN-induced antidiureses was partially inhibited by a high dose of NAL. In addition, the effects of des-Tyr DYN, which does not bind to opioid receptors (31, 32) , in the PVN were markedly weaker, compared with the effects of the same dose of DYN. These findings suggest that DYN elicits antidiureses mediated through opioid receptors, perhaps the K-subtype, in the PVN. On the other hand, the DAKLI-induced antidiureses were not inhibited by NAL. This is probably explained by the low selectivity and affinity for K-receptors of NAL. DAKLI is one of the highest affinity ligands for K-receptors (30) .
Some studies demonstrated diureses or a decrease in vasopressin release by K-agonists injected into the ventri cle (14) (15) (16) . This is not consistent with our present results. The discrepancy is probably due to differences in: 1) action sites of drugs administered and 2) condition of animals used. 1) The drugs, injected into the ventricle, seem to diffuse in it and act in the periventricular tissues. Thus the stimulant would be transferred to several nuclei containing projections from the periventricular tissues. Therefore, the K-agonists injected into the ventricle show the diureses or decrease in vasopressin release as final ac tions. It is likely that the mechanisms underlying will be more than one. The diureses are elicited not only by decreased vasopressin release, but also by an increased glomerular filtration rate of the kidney through the cen tral nervous system (16) . As compared with intra cerebroventricular injection, the action sites of drugs microinjected into the nuclei appear to be limited, be cause methylene blue microinjected into the SON and PVN using the same method does not spread over more than a volume equivalent to a 1-mm cube, and norepi nephrine or oxotremorine microinjected into sites at 1 mm from the nuclei does not show any effects on urine outflow rate (26) (27) (28) . Taken together, the action sites of the drugs administered by the two methods are different from each other. Met-enkephalin is reported to show di ureses by intracerebroventricular injection and anti diureses by microinjection into nuclei (6, 33) . 2) In the studies for the diureses or decrease in vasopressin release by the K-agonists, conscious and non-hydrated (14 16), water-deprived (14) , hydrated (16) or angiotensin II stimulated (15) rats are used. Basal vasopressin level in the plasma under these conditions will be higher than that under the ethanol-anesthetized, ethanol-infused and hydrated condition in the present study, although under the present condition, it is possible to produce diureses by some drugs (this study, ref. 33 ). This may be one of reasons for the discrepancy. It is reported that intra cerebroventricular injection of morphine shows anti diuretic effects, increase in, decrease in or no effects on vasopressin release under various conditions (4) .
On the other hand, microinjection of DYN into the SON produced antidiureses, like those in the PVN. However, the DYN-induced antidiureses were not diminished by the high dose of NAL, and des-Tyr-DYN produced antidiuretic effects equivalent to the DYN induced effects in the SON. From these results, the DYN induced effects in the SON were not mediated through opioid receptors. DYN is reported to have another effect which is not connected with opioid receptors, although the mechanisms have not been clarified (31, 32, 34) . Also, this mechanism may be partially involved in the effects of the PVN, because des-Tyr-DYN produced weak effects in the PVN.
In the SON, the DYN-induced antidiuretic effect was slightly reduced by pretreatment with PHE, TIM and ATR and in the PVN, by pretreatment with TIM and ATR. These findings suggest the possibility that DYN pro motes release of epinephrine/norepinephrine and ACh. However, the intervention of adrenergic and cholinergic neurons in the DYN-induced effects does not seem to be very important, because all the inhibitions were not remarkable. Urine outflow rate is regulated by many mechanisms. Therefore, these inhibitions may reflect the complicated regulation of various neurons. There are a few papers suggesting that DYN and morphine increase transmitter release in the central nervous system in in vivo studies (35, 36) . Many terminals of adrenergic and cholinergic neurons exist in these nuclei (37, 38) . In addi tion, a and ,S-adrenergic, and cholinergic agonists in crease the firing rate of vasopressin-containing neurons or plasma vasopressin level and cause antidiuretic effects in the central nervous system (26-28, 39, 40) .
In both the nuclei, DYN increased vasopressin release. Furthermore, the increase in urinary osmotic pressure, when DYN showed the maximum antidiureses, was almost the same as that of vasopressin injected intra venously. These results suggest that DYN causes anti diureses by increased vasopressin release.
In summary, in the SON and PVN, DYN increased vasopressin release and resulted in the antidiuretic effects involving adrenergic and cholinergic mechanisms. In addition, only the DYN-induced effects in the PVN were mediated, at least partially, through opioid receptors, perhaps the K-subtype.
